Ranibizumab and photodynamic therapy successful

Article

A ranibizumab and photodynamic therapy combination can improve visual acuity and reduce exudation in polypoidal choroidal vasculopathy.

A ranibizumab and photodynamic therapy combination can improve visual acuity and reduce exudation in polypoidal choroidal vasculopathy.

Dr Masaaki Saito et al., Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan, retrospectively reviewed 28 eyes of 28 patients with visual acuity of 20/40 or less. Each patient was treated with three consecutive monthly injections of ranibizumab and underwent photodynamic therapy on day one or two after the injections.

Mean best-corrected vicual acuity (BCVA) improved from 0.33 at baseline to 0/61 at the 12-month follow-up. The mean improvement in BCVA at 12 months from baseline was 2.65 lines.

Central retinal thickness was significantly reduced from 366 µm to 151 µm at 12 months and there were no complications. The combined therapy can be used to maintain or improve visual acuity in polypodal choroidal vasculopathy, as well as reduce exudation without adverse events.

The abstract appeared in the latest edition of the journal Retina.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.